Tragara Pharmaceuticals Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Tragara Pharmaceuticals is a privately held biotechnology company based in Carlsbad, California, focused on the clinical and commercial development of proprietary medicines for cancer treatment. Its program TG02 is an oral multi-kinase inhibitor designed to disrupt cancer cell survival by inhibiting a range of kinases, including CDK9, which lowers levels of survival proteins such as Mcl-1 and can induce apoptosis in diverse tumor types. The company aims to bring therapies that improve patient survival and quality of life.
With a management team drawn from both Big Pharma and biotech, Tragara operates as a small enterprise in the oncology space. In January 2019, the company announced the appointment of Scott Megaffin as Chief Executive Officer and a member of the Board of Directors.

Sign up for free to view info

Company overview Employee directory